Source comparison
CJC-1295 vs IGF-1 LR3: Research Peptide Comparison
The following table compares structural, pharmacokinetic, and mechanistic properties of CJC-1295 and IGF-1 LR3 to clarify their distinct research applications. Mechanism of Action GHRH receptor agonist; stimulates pulsatile GH secretion from anterior pituitary
This comparison does not assign a generated winner or score.
- The following table compares structural, pharmacokinetic, and mechanistic properties of CJC-1295 and IGF-1 LR3 to clarify their distinct research applications.
- Mechanism of Action
- GHRH receptor agonist; stimulates pulsatile GH secretion from anterior pituitary
- Direct IGF-1 receptor agonist; bypasses GH axis entirely
- CJC-1295 for systemic GH/IGF-1 axis studies; IGF-1 LR3 for isolated receptor signaling
- Plasma Half-Life
- 6–8 days (DAC-albumin binding)
- 20–30 hours (reduced IGFBP affinity)
- CJC-1295 allows weekly dosing; IGF-1 LR3 requires daily or every-other-day administration
- Primary Target Tissue
- Pituitary somatotrophs (upstream)
- Muscle, bone, adipose IGF-1 receptors (downstream)
- Choose based on whether your model examines pituitary regulation or peripheral tissue response
- Dosing Frequency in Research Models
- Once or twice weekly (subcutaneous)
- Daily or every 48 hours (subcutaneous)
- CJC-1295's extended half-life reduces injection frequency but delays clearance; IGF-1 LR3 offers tighter temporal control
- Endogenous Feedback Regulation
- Preserved (somatostatin-mediated GH suppression intact)
- Bypassed (no hypothalamic-pituitary involvement)
- CJC-1295 maintains physiological pulse patterns; IGF-1 LR3 delivers constant receptor occupancy
- Suitability for Metabolic Research
- High. Stimulates lipolysis, insulin sensitivity changes, systemic body composition shifts
- Moderate. Tissue-specific glucose uptake and anabolic signaling without GH lipolytic effects
- CJC-1295 preferred for whole-body metabolic studies; IGF-1 LR3 for localized anabolic outcomes
- Suitability for Muscle Hypertrophy Models
- Moderate. Indirect via GH-stimulated hepatic IGF-1 production
- High. Direct mTOR pathway activation and satellite cell proliferation
- IGF-1 LR3 isolates IGF receptor signaling; CJC-1295 involves both GH and IGF-1 mediators
- Bottom Line
- Best for research requiring intact GH axis function, pulsatile hormone patterns, and systemic metabolic effects
- Best for tissue-specific anabolic studies, direct IGF-1 receptor research, and models bypassing pituitary regulation
- CJC-1295 for upstream signaling; IGF-1 LR3 for downstream receptor studies. Select based on biological pathway